ClinicalTrials.gg
Active, not recruitingNCT06477120TRE-PregUpdated Oct 14, 2026

Time-restricted Eating Among Pregnant Females With Severe Obesity

An interventional study of Time Restricted Eating in Obesity, Morbid, Time Restricted Eating and Pregnancy Weight Gain, sponsored by University of Illinois at Chicago. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Prevention

How we know

Updated Oct 14, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Planned enrollment
58th of 150
60 · median 39
Started
2024
with 11 others
No phase
107 of 213
15 open now
Primary completion
2026-09
later than 9 of 34 live
Registered
204th of 213
by date

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 58th largest by planned enrollment of the 150 interventional ones that give a count, is one of 12 that started in 2024, is one of 107 with no phase, reaches primary completion later than 9 of the 34 other live ones, and was the 204th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 44 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

In the United States, a body mass index (BMI) of at least 35.0 kg/m2 affects about 15% of women of reproductive age. Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, birth defects and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. The proposed research aims to assess time-restricted eating in the 2nd and 3rd trimesters of pregnancy to explore the effects on maternal weight, and perinatal health outcomes compared to standard clinical care.

Read the detailed description

Severe obesity is a contributor to adverse perinatal outcomes. The prevalence of severe obesity is on the rise in the United States (U.S.), having increased from 6.4% of the adult population in 2011-2012 to just over 9% of adults in 2017-2018. The prevalence of severe obesity among reproductive age females is approximately 10%. This is an alarming statistic given severe obesity is a predictor of adverse perinatal outcomes including gestational diabetes mellitus, preeclampsia, premature birth (both spontaneous and medically indicated), and at its most severe, fetal death, birth defects, and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. Existing lifestyle interventions (calorie control/dietary pattern changes/physical activity) have showed modest effects on attenuating excess gestational weight gain and modest effects on perinatal health outcomes among pregnant females with obesity. Time- restricted eating, where an individual simply watches the clock and consumes calories within a particular eating window, is a simple and highly accessible eating pattern that has the potential to minimize gestational weight gain, reduce excess glucose and lipids, and improve metabolic health among pregnant females with severe obesity all of which could translate to improved perinatal health outcomes. Yet there are no clinical trials of time-restricted eating in pregnancy. The investigators aim to test the safety, feasibility, and acceptability of time-restricted eating among 60 pregnant females with severe obesity. The investigators will examine time-restricted eating safety, feasibility and acceptability (8-hr eating window in the 2nd trimester \& 10-hr eating window in the 3rd trimester), and explore its effects on weight, cardiometabolic risk markers and perinatal health outcomes vs. Standard Care. The intervention will begin between 14 - \< = 20 weeks gestational age and continue through admission for labor and delivery. The study will involve weekly meetings with a nutritionist, and research visits at baseline (\~17 weeks gestational age), 27-29 weeks gestational age and 35-37 weeks gestational age as well as monthly check-ins for maternal and fetal health monitoring. Maternal and neonatal data from labor and delivery will also be collected from electronic health records. Glucose will be continuously monitored for 10 days at 20 weeks gestational age and 34 weeks gestational age (optional). The goal of our work is to reduce and prevent adverse perinatal outcomes among pregnant females with severe obesity. Given the relative simplicity of time-restricted eating it can be easily disseminated in clinic demonstrating its strong potential for wide-scale public health impact.

03

Conditions studied

  • Obesity, Morbid
  • Time Restricted Eating
  • Pregnancy Weight Gain
04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female based on sex assigned at birth
  • Preconception (BMI) 35.0 - 60 kg/m2
  • Singleton pregnancy
  • Age 18-44 years old
  • 14 - \< = 20 weeks gestational age
  • Fluency in English to provide consent and complete study procedures
  • Ability to provide
  • Cleared by study doctor and the obstetrician/mid-wife provider to participate
  • Access to a smartphone to complete intervention procedures

Exclusion criteria

Exclusion criteria:

  • Deemed medically high risk
  • Multiple pregnancy (e.g., twins)
  • Type 1 or 2 diabetes mellitus
  • Early gestational diabetes (diagnosed at \< = to17 weeks gestational age through an oral glucose tolerance test)
  • Currently eating ≤ 12 hours daily
  • disorder (e.g., rheumatoid arthritis)
  • iron deficiency anemia
  • Inflammatory bowel disease
  • Previous spontaneous preterm birth
  • History of bariatric surgery
  • Night shift work
  • Currently incarcerated
  • Eating disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Time-restricted eating

    Participants randomized to the time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours. During the eating window there will be no restrictions on types or quantities of foods consumed. Moreover, participants will not be required to monitor calorie intake during the ad libitum eating period. During the fasting period, participants will be encouraged to drink plenty of water and will be allowed to consume calorie-free beverages.

    Behavioral: Time Restricted Eating

  • No intervention
    Enhanced Standard Care

    The standard care arm will not receive diet-related counseling. Participants will meet with study staff weekly to record health changes and to transmit weight through the text messaging platform. The remote videoconferencing visits will occur at the same day and time each week. Standard care participants will attend the in-person research data collection visits. Participants will be asked to maintain current (baseline) level of physical activity throughout the intervention.

Interventions

  • BehavioralTime Restricted Eating

    The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily (10am - 6pm OR 11am - 7pm) in the 2nd trimester and 10-hr eating window from (9am - 7pm OR 10am - 8pm) in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.

06

What researchers measure

Primary outcomes

  1. Recruitment Feasibility

    ≥ 30% of those approached enroll

    Time frame: From 6 months through 32 months (the funding period is 36 months)

  2. Trial safety - Maternal Complete Blood Count

    % and n with abnormal results by study arm

    Time frame: Baseline (14-20 weeks gestational age) and monthly through labor and delivery, about 6 months

  3. Trial safety - Non-stress Test for Fetal Safety

    Measured with a fetal monitor to examine baby's heart rate over time (usually 20 to 30 minutes, but sometimes up to an hour) % and n with abnormal results by study arm

    Time frame: 29-31 weeks gestational age and 35-37 weeks gestational age

  4. Intervention acceptability

    Semi-structured interviews

    Time frame: 25-27 weeks gestational age and 35-37 weeks gestational age

  5. Research visit feasibility

    Number of data collection visits completed with \>=80% completed at each timepoint and completeness of data

    Time frame: Baseline, 25-27 weeks gestational age and 35-37 weeks gestational age

  6. Intervention (TRE) session feasibility

    Number and % of intervention sessions completed by TRE participants

    Time frame: Weekly from baseline through labor and delivery, about 6 months

  7. TRE adherence

    Response rate to daily text message regarding eating start and stop time to determine adherence to the eating window goal is \>= 80% adherence on days reported

    Time frame: Daily from enrollment to labor and delivery (TRE arm only), about 6 months

  8. Trial safety - Maternal health checks

    Weekly maternal health checks via videoconference in TRE and control group that is verified with electronic health record

    Time frame: Weekly from baseline to labor and delivery, about 6 months, % and n for health events reported by study arm

  9. Trial safety - Maternal outcomes

    Data obtained from the participant's electronic health record (gestational age at delivery, gestational diabetes, gestational hypertension, preeclampsia, c-section, spontaneous pre-term birth, iron deficiency anemia) % and n with abnormal results by study arm

    Time frame: Labor and delivery

  10. Trial safety - Neonatal outcomes

    Data obtained from the participant's electronic health record (small or large for gestational age, neonatal intensive care admission, jaundice, APGAR score) % and n with abnormal results by study arm

    Time frame: Labor and delivery

  11. Trial Retention

    n and % of women retained through the final in-person data collection with \>= 80% retained

    Time frame: 35-37 week gestational age

Secondary outcomes

  1. Maternal Body Weight

    Body weight in kilograms

    Time frame: Baseline (14-20 weeks), 25-27 weeks gestational age, 35-37 weeks gestational age

  2. Maternal Fasting Blood Glucose

    Measured in serum

    Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age

  3. Maternal Fasting Insulin

    Measured in serum

    Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age

  4. Maternal Fasting Blood Lipids

    Cholesterol and triglycerides

    Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age

  5. Maternal C-reactive protein

    Measured in plasma

    Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age

  6. Maternal Systolic Blood Pressure

    Measured with participant in a seated position using an automated cuff

    Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age

  7. Maternal Diastolic Blood Pressure

    Measured with participant in a seated position using an automated cuff

    Time frame: Baseline (14-20 weeks), 25-27 weeks gestational age, 35-37 weeks gestational age

  8. Maternal Hb A1c

    Measured from whole blood

    Time frame: Baseline (14-20 weeks gestational age), 25-27 weeks gestational age, 35-37 weeks gestational age

07

Study locations

1 site
  • University of Illinois at Chicago College of Applied Health Sciences
    Chicago, Illinois 60612, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Sep 2026, 24 months.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 24 months is close to that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 27, 2024
StartActual
Sep 9, 2024
Primary completionActual
Sep 16, 2026was Aug 2026
CompletionEst.
Nov 29, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 14, 2026
Primary completion
Aug 31, 2026→Sep 16, 2026 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Active, not recruiting
    Primary completion Aug 31, 2026→Sep 16, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06477120
Responsible party
Lisa Tussing-Humphreys (Professor, Kinesiology and Nutrition, PhD, MS, RD, University of Illinois at Chicago) — Principal investigator
First posted
Jun 27, 2024
Start date
Sep 9, 2024
Primary completion
Sep 16, 2026
Completion
Nov 29, 2026 (estimated)
Last update
Oct 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion